{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:42Z","timestamp":1784822622508,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00959-3","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:26:56Z","timestamp":1780662416000},"page":"1917-1929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing\u2013Remitting Multiple Sclerosis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3497-0382","authenticated-orcid":false,"given":"Clair-Antoine","family":"Veyrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0997-8817","authenticated-orcid":false,"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8261-5302","authenticated-orcid":false,"given":"Olivier","family":"Casez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4634-8542","authenticated-orcid":false,"given":"Olivier","family":"Heinzlef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8375-7530","authenticated-orcid":false,"given":"Marianne","family":"Payet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3683-5582","authenticated-orcid":false,"given":"Nicolas","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-2255","authenticated-orcid":false,"given":"Martin","family":"Duracinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"959_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.neurol.2023.12.007","volume":"180","author":"C Pierret","year":"2024","unstructured":"Pierret C, Mainguy M, Leray E. Prevalence of multiple sclerosis in France in 2021: data from the French health insurance database. Rev Neurol Paris. 2024;180:429\u201337. https:\/\/doi.org\/10.1016\/j.neurol.2023.12.007.","journal-title":"Rev Neurol Paris"},{"key":"959_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","volume":"15","author":"CB Vaughn","year":"2019","unstructured":"Vaughn CB, Jakimovski D, Kavak KS, et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol. 2019;15:329\u201342. https:\/\/doi.org\/10.1038\/s41582-019-0183-3.","journal-title":"Nat Rev Neurol"},{"key":"959_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-021-07012-z","volume":"21","author":"A Sippel","year":"2021","unstructured":"Sippel A, Riemann-Lorenz K, Scheiderbauer J, et al. Patients experiences with multiple sclerosis disease-modifying therapies in daily life\u2014a qualitative interview study. BMC Health Serv Res. 2021;21:1\u201312. https:\/\/doi.org\/10.1186\/s12913-021-07012-z.","journal-title":"BMC Health Serv Res"},{"key":"959_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2147\/PPA.S142373","volume":"11","author":"G Lee Mortensen","year":"2017","unstructured":"Lee Mortensen G, Rasmussen PV. The impact of quality of life on treatment preferences in multiple sclerosis patients. PPA. 2017;11:1789\u201396. https:\/\/doi.org\/10.2147\/PPA.S142373.","journal-title":"PPA"},{"key":"959_CR5","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1007\/s40120-025-00817-8","volume":"14","author":"J Chojdak-\u0141ukasiewicz","year":"2025","unstructured":"Chojdak-\u0141ukasiewicz J, Ku\u0142akowska A, Tarasiuk J, et al. Perspective of disease and treatment in patients with multiple sclerosis: a Polish multi-center study. Neurol Ther. 2025;14:2453\u201375. https:\/\/doi.org\/10.1007\/s40120-025-00817-8.","journal-title":"Neurol Ther"},{"key":"959_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/0272989X19897944","volume":"40","author":"MF Jonker","year":"2020","unstructured":"Jonker MF, Donkers B, Goossens LMA, et al. Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options. Med Decis Making. 2020;40:198\u2013211. https:\/\/doi.org\/10.1177\/0272989X19897944.","journal-title":"Med Decis Making"},{"key":"959_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/PROM.S34681","volume":"3","author":"D Eton","year":"2012","unstructured":"Eton D, Ramalho de Oliveira D, Egginton J, et al. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. Patient Relat Outcome Meas. 2012;3:39\u201349. https:\/\/doi.org\/10.2147\/PROM.S34681.","journal-title":"Patient Relat Outcome Meas"},{"key":"959_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19042203","volume":"19","author":"A Ko\u0142tuniuk","year":"2022","unstructured":"Ko\u0142tuniuk A, Chojdak-\u0141ukasiewicz J. Adherence to therapy in patients with multiple sclerosis\u2014review. Int J Environ Res Public Health. 2022;19:2203. https:\/\/doi.org\/10.3390\/ijerph19042203.","journal-title":"Int J Environ Res Public Health"},{"key":"959_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/13524585211005339","volume":"28","author":"E Portaccio","year":"2022","unstructured":"Portaccio E, Fonderico M, Hemmer B, et al. Impact of COVID-19 on multiple sclerosis care and management: results from the European Committee for treatment and research in multiple sclerosis survey. Mult Scler. 2022;28:132\u20138. https:\/\/doi.org\/10.1177\/13524585211005339.","journal-title":"Mult Scler"},{"key":"959_CR10","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1007\/s00415-020-10029-9","volume":"267","author":"AL Kaminsky","year":"2020","unstructured":"Kaminsky AL, Omorou AY, Soudant M, et al. Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease inactivity. J Neurol. 2020;267:3518\u201327. https:\/\/doi.org\/10.1007\/s00415-020-10029-9.","journal-title":"J Neurol"},{"key":"959_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103490","volume":"58","author":"G Disanto","year":"2022","unstructured":"Disanto G, Moccia M, Sacco R, et al. Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50\u00a0years. Mult Scler Relat Disord. 2022;58:103490. https:\/\/doi.org\/10.1016\/j.msard.2022.103490.","journal-title":"Mult Scler Relat Disord"},{"key":"959_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286420969016","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Gonzalez Caldito N, Shirani A, et al. Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. Ther Adv Neurol Disord. 2020;13:1\u201310. https:\/\/doi.org\/10.1177\/1756286420969016.","journal-title":"Ther Adv Neurol Disord"},{"key":"959_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14737175.2021.1886082","volume":"21","author":"D Jakimovski","year":"2021","unstructured":"Jakimovski D, Eckert SP, Zivadinov R, Weinstock-Guttman B. Considering patient age when treating multiple sclerosis across the adult lifespan. Expert Rev Neurother. 2021;21:353\u201364. https:\/\/doi.org\/10.1080\/14737175.2021.1886082.","journal-title":"Expert Rev Neurother"},{"key":"959_CR14","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00415-021-10850-w","volume":"269","author":"F Washington","year":"2022","unstructured":"Washington F, Langdon D. Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review. J Neurol. 2022;269:1861\u201372. https:\/\/doi.org\/10.1007\/s00415-021-10850-w.","journal-title":"J Neurol"},{"key":"959_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.474","volume":"5","author":"SCL Caseby","year":"2022","unstructured":"Caseby SCL, Woodhouse FA, Montgomery SM, Kroes MA, Duddy ME. Transition to secondary progressive multiple sclerosis: the consequences for patients and healthcare systems, a healthcare professional survey. Health Sci Rep. 2022;5:e474. https:\/\/doi.org\/10.1002\/hsr2.474.","journal-title":"Health Sci Rep"},{"key":"959_CR16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40120-021-00265-0","volume":"10","author":"S Lewis","year":"2021","unstructured":"Lewis S, Wray SE, Evans E, et al. Patients\u2019 experiences in transitioning to secondary progressive multiple sclerosis: qualitative interviews. Neurol Ther. 2021;10:887\u2013904. https:\/\/doi.org\/10.1007\/s40120-021-00265-0.","journal-title":"Neurol Ther"},{"key":"959_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102507","volume":"46","author":"A Manzano","year":"2020","unstructured":"Manzano A, Eskyt\u00e9 I, Ford HL, et al. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020;46:102507. https:\/\/doi.org\/10.1016\/j.msard.2020.102507.","journal-title":"Mult Scler Relat Disord"},{"key":"959_CR18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.18553\/jmcp.2021.27.9.1273","volume":"27","author":"J Mardan","year":"2021","unstructured":"Mardan J, Hussain MA, Allan M, Grech LB. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. JMCP. 2021;27:1273\u201395. https:\/\/doi.org\/10.18553\/jmcp.2021.27.9.1273.","journal-title":"JMCP"},{"key":"959_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.7224\/1537-2073.2021-139","volume":"25","author":"AB Ben-Zacharia","year":"2023","unstructured":"Ben-Zacharia AB, Walker B, Ross AP, et al. Factors associated with disease-modifying therapy adherence and persistence in multiple sclerosis: a scoping literature review. Int J MS Care. 2023;25:188\u201395. https:\/\/doi.org\/10.7224\/1537-2073.2021-139.","journal-title":"Int J MS Care"},{"key":"959_CR20","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.18553\/jmcp.2013.19.s1.S24","volume":"19","author":"J Menzin","year":"2013","unstructured":"Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. JMCP. 2013;19:S24-40. https:\/\/doi.org\/10.18553\/jmcp.2013.19.s1.S24.","journal-title":"JMCP"},{"key":"959_CR21","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.18553\/jmcp.2016.22.12.1394","volume":"22","author":"L Higuera","year":"2016","unstructured":"Higuera L, Carlin CS, Anderson S. Adherence to disease-modifying therapies for multiple sclerosis. JMCP. 2016;22:1394\u2013401. https:\/\/doi.org\/10.18553\/jmcp.2016.22.12.1394.","journal-title":"JMCP"},{"key":"959_CR22","doi-asserted-by":"publisher","unstructured":"Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. 1st ed. Routledge; 1999. https:\/\/doi.org\/10.4324\/9780203793206","DOI":"10.4324\/9780203793206"},{"key":"959_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19:349\u201357. https:\/\/doi.org\/10.1093\/intqhc\/mzm042.","journal-title":"Int J Qual Health Care"},{"key":"959_CR24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21:839\u201342. https:\/\/doi.org\/10.1016\/j.jval.2017.11.014.","journal-title":"Value Health"},{"key":"959_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1586\/erp.10.30","volume":"10","author":"C Kerr","year":"2010","unstructured":"Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2010;10:269\u201381. https:\/\/doi.org\/10.1586\/erp.10.30.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"959_CR26","unstructured":"Dr\u00f6ge K. noScribe. AI-powered Audio Transcription [Internet]. 2025. https:\/\/github.com\/kaixxx\/noScribe. Accessed 22 May 2026."},{"key":"959_CR27","unstructured":"ELAN [Internet]. Nijmegen, the Netherlands: Max Planck Institute for Psycholinguistics; 2025. https:\/\/archive.mpi.nl\/tla\/elan. Accessed 22 May 2026."},{"key":"959_CR28","doi-asserted-by":"publisher","DOI":"10.5430\/jnep.v6n5p100","volume":"6","author":"M Vaismoradi","year":"2016","unstructured":"Vaismoradi M, Jones J, Turunen H, Snelgrove S. Theme development in qualitative content analysis and thematic analysis. J Nurs Educ Pract. 2016;6:100. https:\/\/doi.org\/10.5430\/jnep.v6n5p100.","journal-title":"J Nurs Educ Pract"},{"key":"959_CR29","volume-title":"Transforming qualitative information: thematic analysis and code development","author":"RE Boyatzis","year":"1998","unstructured":"Boyatzis RE. Transforming qualitative information: thematic analysis and code development. Thousand Oaks: Sage; 1998."},{"key":"959_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1098214005283748","volume":"27","author":"D Thomas","year":"2006","unstructured":"Thomas D. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27:237\u201346. https:\/\/doi.org\/10.1177\/1098214005283748.","journal-title":"Am J Eval"},{"key":"959_CR31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1188\/14.ONF.545-547","volume":"41","author":"N Carter","year":"2014","unstructured":"Carter N, Bryant-Lukosius D, DiCenso A, Blythe J, Neville AJ. The use of triangulation in qualitative research. Oncol Nurs Forum. 2014;41:545\u20137. https:\/\/doi.org\/10.1188\/14.ONF.545-547.","journal-title":"Oncol Nurs Forum"},{"key":"959_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103915","volume":"63","author":"R Alonso","year":"2022","unstructured":"Alonso R, Rojas JI, Ramos J, et al. Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America. Mult Scler Relat Disord. 2022;63:103915. https:\/\/doi.org\/10.1016\/j.msard.2022.103915.","journal-title":"Mult Scler Relat Disord"},{"key":"959_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016532","volume":"98","author":"F Corallo","year":"2019","unstructured":"Corallo F, Bonanno L, Di Cara M, et al. Therapeutic adherence and coping strategies in patients with multiple sclerosis: an observational study. Medicine. 2019;98:e16532. https:\/\/doi.org\/10.1097\/MD.0000000000016532.","journal-title":"Medicine"},{"key":"959_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.7224\/1537-2073.2017-109","volume":"20","author":"LD Lynd","year":"2018","unstructured":"Lynd LD, Henrich NJ, Hategeka C, et al. Perspectives of patients with multiple sclerosis on drug treatment: a qualitative study. Int J MS Care. 2018;20:269\u201377. https:\/\/doi.org\/10.7224\/1537-2073.2017-109.","journal-title":"Int J MS Care"},{"key":"959_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102016","volume":"41","author":"K Stratos","year":"2020","unstructured":"Stratos K, McGarragle K, Thistle J, Vyas MV, Lee L. Non-compliance with disease modifying therapies in patients with multiple sclerosis: a qualitative analysis. Mult Scler Relat Disord. 2020;41:102016. https:\/\/doi.org\/10.1016\/j.msard.2020.102016.","journal-title":"Mult Scler Relat Disord"},{"key":"959_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/1352458518816619","volume":"26","author":"CB Vaughn","year":"2020","unstructured":"Vaughn CB, Kavak KS, Dwyer MG, et al. Fatigue at enrollment predicts EDSS worsening in the New York state multiple sclerosis consortium. Mult Scler. 2020;26:99\u2013108. https:\/\/doi.org\/10.1177\/1352458518816619.","journal-title":"Mult Scler"},{"key":"959_CR37","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s40120-025-00806-x","volume":"14","author":"E Smith","year":"2025","unstructured":"Smith E, Langdon D. Treatment adherence in MS: does objective MS knowledge and MS risk knowledge matter in relation to perceived disease-modifying therapy benefits? Neurol Ther. 2025;14:2107\u201323. https:\/\/doi.org\/10.1007\/s40120-025-00806-x.","journal-title":"Neurol Ther"},{"key":"959_CR38","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s40120-024-00654-1","volume":"13","author":"BA Singer","year":"2024","unstructured":"Singer BA, Morgan D, Stamm JA, Williams AA. Patient and physician perspectives of treatment burden in multiple sclerosis. Neurol Ther. 2024;13:1507\u201325. https:\/\/doi.org\/10.1007\/s40120-024-00654-1.","journal-title":"Neurol Ther"},{"key":"959_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/CEOR.S489929","volume":"17","author":"B Talente","year":"2025","unstructured":"Talente B, Finseth L, Blake N, et al. Patient experiences with the impacts of multiple sclerosis & disease-modifying therapies. CEOR. 2025;17:199\u2013215. https:\/\/doi.org\/10.2147\/CEOR.S489929.","journal-title":"CEOR"},{"key":"959_CR40","doi-asserted-by":"publisher","first-page":"363","DOI":"10.7224\/1537-2073.2024-012","volume":"26","author":"SC Silverman","year":"2024","unstructured":"Silverman SC, Yang B, Mata-Greve F, et al. Multiple sclerosis fatigue self-management: strategies and influencing factors 5\u00a0years after a multimodal intervention. Int J MS Care. 2024;26:363\u20139. https:\/\/doi.org\/10.7224\/1537-2073.2024-012.","journal-title":"Int J MS Care"},{"key":"959_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13182335","volume":"13","author":"S Poli","year":"2025","unstructured":"Poli S, Donisi V, Das Nair R, Mazzi MA, Gajofatto A, Rimondini M. Psychosocial correlates of fatigue in young adults with multiple sclerosis: exploring the roles of resilience, mindfulness, and illness perception. Healthcare. 2025;13:2335. https:\/\/doi.org\/10.3390\/healthcare13182335.","journal-title":"Healthcare"},{"key":"959_CR42","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2147\/PPA.S129678","volume":"11","author":"FD Alosaimi","year":"2017","unstructured":"Alosaimi FD, AlMulhem A, AlShalan H, et al. Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis. PPA. 2017;11:513\u20138. https:\/\/doi.org\/10.2147\/PPA.S129678.","journal-title":"PPA"},{"key":"959_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1565150","volume":"16","author":"R G\u00f3mez-Ballesteros","year":"2025","unstructured":"G\u00f3mez-Ballesteros R, Sainz De La Maza S, Borges M, et al. Threatening illness perception and associated factors in early-stage relapsing-remitting multiple sclerosis. Front Psychiatry. 2025;16:1565150. https:\/\/doi.org\/10.3389\/fpsyt.2025.1565150.","journal-title":"Front Psychiatry"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00959-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00959-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00959-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:34Z","timestamp":1784819494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00959-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["959"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00959-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Laura Luciani and Marianne Payet are employees of Merck Sant\u00e9 S.A.S., Lyon, France, an affiliate of Merck KGaA. Olivier Casez: Honorarium Biogen, Sanofi-Genzyme, Novartis, Merck, Roche, Janssen, Juvis\u00e9, Alexion, Coloplast and Amgen. Patrick Vermersch: Honorarium Biogen, Sanofi Genzyme, Novartis, Teva, Merck Serono S.A.S, Lyon, France, an affiliate of Merck KGaA, Roche, Imcyse, AB Science, Janssen, Ad Scientiam and BMS. Nicolas Collongues: Honorarium Alexion, Biogen Idec, Bristol-Myers Squibb, Horizon Therapeutics, Merck Sant\u00e9 S.A.S., Lyon, France, an affiliate of Merck KGaA, Novartis, Roche, Sanofi-Genzyme. Olivier Heinzlef: Honorarium Merck Sant\u00e9 S.A.S., Lyon, France, an affiliate of Merck KGaA, Almirall, Bayer Schering, Biogen Idec, Genzyme, Janssen Cilag, Novartis, Roche, Sanofi, Teva. Martin Duracinsky: Honorarium Merck Sant\u00e9 S.A.S. Clair-Antoine Veyrier declares no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved on October 29, 2024 (CER-2024-268) by Institutional Review Board Comit\u00e9 d\u2019Ethique de la Recherche (CER) Paris Nord (IRB 00006477) of HUPNVS, Paris Cit\u00e9 University, AP-HP. All subjects provided informed consent to participate in the study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}